Cargando…
Bacteriophage Therapy for Difficult-to-Treat Infections: The Implementation of a Multidisciplinary Phage Task Force (The PHAGEFORCE Study Protocol)
In times where only a few novel antibiotics are to be expected, antimicrobial resistance remains an expanding global health threat. In case of chronic infections caused by therapy-resistant pathogens, physicians have limited therapeutic options, which are often associated with detrimental consequenc...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402896/ https://www.ncbi.nlm.nih.gov/pubmed/34452408 http://dx.doi.org/10.3390/v13081543 |
_version_ | 1783745901068550144 |
---|---|
author | Onsea, Jolien Uyttebroek, Saartje Chen, Baixing Wagemans, Jeroen Lood, Cédric Van Gerven, Laura Spriet, Isabel Devolder, David Debaveye, Yves Depypere, Melissa Dupont, Lieven De Munter, Paul Peetermans, Willy E. van Noort, Vera Merabishvili, Maia Pirnay, Jean-Paul Lavigne, Rob Metsemakers, Willem-Jan |
author_facet | Onsea, Jolien Uyttebroek, Saartje Chen, Baixing Wagemans, Jeroen Lood, Cédric Van Gerven, Laura Spriet, Isabel Devolder, David Debaveye, Yves Depypere, Melissa Dupont, Lieven De Munter, Paul Peetermans, Willy E. van Noort, Vera Merabishvili, Maia Pirnay, Jean-Paul Lavigne, Rob Metsemakers, Willem-Jan |
author_sort | Onsea, Jolien |
collection | PubMed |
description | In times where only a few novel antibiotics are to be expected, antimicrobial resistance remains an expanding global health threat. In case of chronic infections caused by therapy-resistant pathogens, physicians have limited therapeutic options, which are often associated with detrimental consequences for the patient. This has resulted in a renewed interest in alternative strategies, such as bacteriophage (phage) therapy. However, there are still important hurdles that currently impede the more widespread implementation of phage therapy in clinical practice. First, the limited number of good-quality case series and clinical trials have failed to show the optimal application protocol in terms of route of administration, frequency of administration, treatment duration and phage titer. Second, there is limited information on the systemic effects of phage therapy. Finally, in the past, phage therapy has been applied intuitively in terms of the selection of phages and their combination as parts of phage cocktails. This has led to an enormous heterogeneity in previously published studies, resulting in a lack of reliable safety and efficacy data for phage therapy. We hereby present a study protocol that addresses these scientific hurdles using a multidisciplinary approach, bringing together the experience of clinical, pharmaceutical and molecular microbiology experts. |
format | Online Article Text |
id | pubmed-8402896 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84028962021-08-29 Bacteriophage Therapy for Difficult-to-Treat Infections: The Implementation of a Multidisciplinary Phage Task Force (The PHAGEFORCE Study Protocol) Onsea, Jolien Uyttebroek, Saartje Chen, Baixing Wagemans, Jeroen Lood, Cédric Van Gerven, Laura Spriet, Isabel Devolder, David Debaveye, Yves Depypere, Melissa Dupont, Lieven De Munter, Paul Peetermans, Willy E. van Noort, Vera Merabishvili, Maia Pirnay, Jean-Paul Lavigne, Rob Metsemakers, Willem-Jan Viruses Study Protocol In times where only a few novel antibiotics are to be expected, antimicrobial resistance remains an expanding global health threat. In case of chronic infections caused by therapy-resistant pathogens, physicians have limited therapeutic options, which are often associated with detrimental consequences for the patient. This has resulted in a renewed interest in alternative strategies, such as bacteriophage (phage) therapy. However, there are still important hurdles that currently impede the more widespread implementation of phage therapy in clinical practice. First, the limited number of good-quality case series and clinical trials have failed to show the optimal application protocol in terms of route of administration, frequency of administration, treatment duration and phage titer. Second, there is limited information on the systemic effects of phage therapy. Finally, in the past, phage therapy has been applied intuitively in terms of the selection of phages and their combination as parts of phage cocktails. This has led to an enormous heterogeneity in previously published studies, resulting in a lack of reliable safety and efficacy data for phage therapy. We hereby present a study protocol that addresses these scientific hurdles using a multidisciplinary approach, bringing together the experience of clinical, pharmaceutical and molecular microbiology experts. MDPI 2021-08-05 /pmc/articles/PMC8402896/ /pubmed/34452408 http://dx.doi.org/10.3390/v13081543 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Study Protocol Onsea, Jolien Uyttebroek, Saartje Chen, Baixing Wagemans, Jeroen Lood, Cédric Van Gerven, Laura Spriet, Isabel Devolder, David Debaveye, Yves Depypere, Melissa Dupont, Lieven De Munter, Paul Peetermans, Willy E. van Noort, Vera Merabishvili, Maia Pirnay, Jean-Paul Lavigne, Rob Metsemakers, Willem-Jan Bacteriophage Therapy for Difficult-to-Treat Infections: The Implementation of a Multidisciplinary Phage Task Force (The PHAGEFORCE Study Protocol) |
title | Bacteriophage Therapy for Difficult-to-Treat Infections: The Implementation of a Multidisciplinary Phage Task Force (The PHAGEFORCE Study Protocol) |
title_full | Bacteriophage Therapy for Difficult-to-Treat Infections: The Implementation of a Multidisciplinary Phage Task Force (The PHAGEFORCE Study Protocol) |
title_fullStr | Bacteriophage Therapy for Difficult-to-Treat Infections: The Implementation of a Multidisciplinary Phage Task Force (The PHAGEFORCE Study Protocol) |
title_full_unstemmed | Bacteriophage Therapy for Difficult-to-Treat Infections: The Implementation of a Multidisciplinary Phage Task Force (The PHAGEFORCE Study Protocol) |
title_short | Bacteriophage Therapy for Difficult-to-Treat Infections: The Implementation of a Multidisciplinary Phage Task Force (The PHAGEFORCE Study Protocol) |
title_sort | bacteriophage therapy for difficult-to-treat infections: the implementation of a multidisciplinary phage task force (the phageforce study protocol) |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402896/ https://www.ncbi.nlm.nih.gov/pubmed/34452408 http://dx.doi.org/10.3390/v13081543 |
work_keys_str_mv | AT onseajolien bacteriophagetherapyfordifficulttotreatinfectionstheimplementationofamultidisciplinaryphagetaskforcethephageforcestudyprotocol AT uyttebroeksaartje bacteriophagetherapyfordifficulttotreatinfectionstheimplementationofamultidisciplinaryphagetaskforcethephageforcestudyprotocol AT chenbaixing bacteriophagetherapyfordifficulttotreatinfectionstheimplementationofamultidisciplinaryphagetaskforcethephageforcestudyprotocol AT wagemansjeroen bacteriophagetherapyfordifficulttotreatinfectionstheimplementationofamultidisciplinaryphagetaskforcethephageforcestudyprotocol AT loodcedric bacteriophagetherapyfordifficulttotreatinfectionstheimplementationofamultidisciplinaryphagetaskforcethephageforcestudyprotocol AT vangervenlaura bacteriophagetherapyfordifficulttotreatinfectionstheimplementationofamultidisciplinaryphagetaskforcethephageforcestudyprotocol AT sprietisabel bacteriophagetherapyfordifficulttotreatinfectionstheimplementationofamultidisciplinaryphagetaskforcethephageforcestudyprotocol AT devolderdavid bacteriophagetherapyfordifficulttotreatinfectionstheimplementationofamultidisciplinaryphagetaskforcethephageforcestudyprotocol AT debaveyeyves bacteriophagetherapyfordifficulttotreatinfectionstheimplementationofamultidisciplinaryphagetaskforcethephageforcestudyprotocol AT depyperemelissa bacteriophagetherapyfordifficulttotreatinfectionstheimplementationofamultidisciplinaryphagetaskforcethephageforcestudyprotocol AT dupontlieven bacteriophagetherapyfordifficulttotreatinfectionstheimplementationofamultidisciplinaryphagetaskforcethephageforcestudyprotocol AT demunterpaul bacteriophagetherapyfordifficulttotreatinfectionstheimplementationofamultidisciplinaryphagetaskforcethephageforcestudyprotocol AT peetermanswillye bacteriophagetherapyfordifficulttotreatinfectionstheimplementationofamultidisciplinaryphagetaskforcethephageforcestudyprotocol AT vannoortvera bacteriophagetherapyfordifficulttotreatinfectionstheimplementationofamultidisciplinaryphagetaskforcethephageforcestudyprotocol AT merabishvilimaia bacteriophagetherapyfordifficulttotreatinfectionstheimplementationofamultidisciplinaryphagetaskforcethephageforcestudyprotocol AT pirnayjeanpaul bacteriophagetherapyfordifficulttotreatinfectionstheimplementationofamultidisciplinaryphagetaskforcethephageforcestudyprotocol AT lavignerob bacteriophagetherapyfordifficulttotreatinfectionstheimplementationofamultidisciplinaryphagetaskforcethephageforcestudyprotocol AT metsemakerswillemjan bacteriophagetherapyfordifficulttotreatinfectionstheimplementationofamultidisciplinaryphagetaskforcethephageforcestudyprotocol |